1.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: CR01/18/10, NCT01189903
|
|
2.
|
Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 75 Sponsor: Other Protocol IDs: EORTC-1207, 2012-002317-18, NCT01646554
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HEPATICA, NCT00394992
|
|
4.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: FIRE-3, NCT00433927
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000549541, USCTU-4351, USCTU-EPOC, EUDRACT-2006-003121-82, ISRCTN22944367, EU-20732, EPOC, NCT00482222
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 20 to 79 Sponsor: Other Protocol IDs: ICOG-CC01, NCT00497107
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-000354-31, NCT00646607
|
|
8.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000598567, GONO-BEBYP-ASL607LIOM03, GONO-AIFA - FARM5C4FB4, EUDRACT:2007-002886-11, GONO– ASL607LIOM03, EU-20860, NCT00720512
|
|
9.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000598582, GONO-TRIBE, ASL608LIOM04, EUDRACT:2008-001537-10, TRIBE, EU-20859, NCT00719797
|
|
10.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: SICOG-0803, SICOG 0803, MARTHA, EudraCT-2008-004890-17, NCT00797485
|
|
11.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20080259, NCT00911170
|
|
12.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ML 25359, NCT01229813
|
|
13.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: ML22011, NCT01249638
|
|
14.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 70 and over Sponsor: NCI Protocol IDs: NCCTG-N0949, N0949, NCT01279681
|
|
15.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: CPP-450, 2010-019140-39, NCT01317433
|
|
16.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AFLIBC06097, 2011-005724-17, U1111-1125-8949, NCT01571284
|
|
17.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 15808, NCT01584830
|
|
18.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CAIRO4, NCT01606098
|
|
19.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: TTD-12-01, 2012-000846-37, NCT01640405
|
|
20.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AFLIBL06266, 2012-000048-89, U1111-1128-9325, NCT01670721
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC11338, U1111-1115-7227, NCT01661270
|